ArticleNeurology and therapy2025
Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson's Disease: A Swedish Study on Real-World Use and Costs.
Article in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Continuous infusion therapy after deep brain stimulation in Parkinson's disease: indications, outcomes, and patient selection.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Clinical Outcomes and Predictors of Response to Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: A Retrospective Cohort Study over a 4-Year Period.Pharmaceutics · 2026Article
- Response to "Letter to the Editor" Regarding Odin P, et al. 2025 'Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson's Disease: A Swedish Study on Real-World Use and Costs'.Neurology and therapy · 2026Article
- Letter to the Editor Regarding 'Levodopa Intestinal Gel Infusion Therapies in Advanced Parkinson's Disease: A Swedish Study on Real-World Use and Costs'.Neurology and therapy · 2026Article
- Long-Term Effectiveness and Safety of LCIG in Romania. 3-year Results from a Prospective, Observational Study (DUOGLOBE).Neuropsychiatric disease and treatment · 2026Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study evaluated real-world cassette use and cost of levodopa-carbidopa intestinal gel (LCIG; 2000 mg levodopa equivalent dose [LED]) and levodopa-entacapone-carbidopa intestinal gel (LECIG; 1250 mg LED) pump treatments among patients with advanced Parkinson's disease (PD) in Sweden.
methodsThis was a non-interventional, longitudinal, retrospective, comparative study of patients with PD using data from Swedish national registries (National Patient Register [NPR] and Prescribed Drug Register [PDR]). Patients were enrolled in the study from January 1, 2017, to May 31, 2022 (NPR) or June 30, 2022 (PDR). Patients had two or more dispensed prescription records for either LCIG (January 1, 2017, onward) or LECIG (January 1, 2019, onward) and at least one diagnosis of PD on or before their first dispensed prescription. Average daily cassette use, costs (Swedish krona [SEK]), treatment persistence, and treatment patterns were assessed.
resultsOverall, 419 patients (LCIG, n = 276; LECIG, n = 180; both LCIG and LECIG, n = 37 [cohorts not mutually exclusive]) were included. Mean (SD) daily cassette use was significantly higher for LECIG than for LCIG: 1.28 (0.40) versus 1.09 (0.28) at 1-365 days (p < 0.0001). LECIG use was higher than LCIG at 365 days regardless of prior levodopa pump experience. The overall cost of LECIG was higher than that of LCIG; the highest cost difference between treatments was at 365 days (daily cost mean [SD], LCIG 991.23 [259.43] SEK vs. LECIG 1100.23 [341.04] SEK; p = 0.0036). Annual per-patient costs were approximately 40,000 SEK higher for LECIG versus LCIG. More patients discontinued LECIG than LCIG treatment, with 68.9% and 75.2% of those receiving LECIG and LCIG, respectively, still on treatment at 365 days.
conclusionReal-world data show that the number of dispensed cassettes and overall treatment costs are higher for LECIG than LCIG treatment among patients with advanced PD in Sweden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.